<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19998">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899911</url>
  </required_header>
  <id_info>
    <org_study_id>CD-0024</org_study_id>
    <nct_id>NCT01899911</nct_id>
  </id_info>
  <brief_title>Clinical Study of SpO2: Vital Signs Patch</brief_title>
  <official_title>Pulse Oximeter Response TO Multiple Levels Of Stable Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeWatch Technologies Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LifeWatch Technologies Ltd.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study designed to  determine the accuracy of the SpO2 function of the Vital Signs
      Patch device for measuring blood saturation level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study protocol was designed  for  determining the accuracy of the SpO2 function
      of the Vital Signs Patch device for measuring blood oxygen saturation level,  according to
      the guidelines for &quot;evaluating and documenting SpO2 accuracy in human subjects&quot; as set out
      in Annex EE of ISO 80601-2-61. Section 4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>SPO2 level</measure>
    <time_frame>within 24 hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Infrared and red light absorbency was measured and used for SpO2 percentage calculation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Desaturation of Blood</condition>
  <arm_group>
    <arm_group_label>VSP-Vital Signs Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infrared and Red absorbance measurement on chest</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VSP</intervention_name>
    <description>Infrared and red absorbance measurement</description>
    <arm_group_label>VSP-Vital Signs Patch</arm_group_label>
    <other_name>Vital signs Patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 23 to 33.

          -  Skin tone varied from light to dark.

        Exclusion Criteria:

          -  Smokers

          -  Anemic
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>33 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip E. , Bickler, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Room M454, Moffitt Hospital, Box 0542, UCSF,</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>CA 94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 15, 2013</lastchanged_date>
  <firstreceived_date>July 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
